This company has been marked as potentially delisted and may not be actively trading. POINT Biopharma Global (PNT) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Prota Therapeutics Strengthens Board with Appointment of Global Biotech Expert Patrick MachadoJuly 24, 2024 | markets.businessinsider.comWhat's Going On With GT Biopharma Stock?May 20, 2024 | msn.comInvesting in biopharma innovation: Can you stay one step ahead?April 8, 2024 | bloomberg.comDomain Therapeutics Strengthens Leadership Team to Spearhead Global Development and North American Expansion as the Leading GPCR Immuno-Oncology CompanyJanuary 8, 2024 | businesswire.comLilly Completes Acquisition of POINT BiopharmaDecember 27, 2023 | finance.yahoo.comTrading was temporarily halted for "PNT" at 07:12 PM with a stated reason of "News pending."December 27, 2023 | marketbeat.comPOINT Biopharma Global Rating Adjustment: Hold Recommendation Following Shareholder Dynamics and Acquisition ProspectsDecember 22, 2023 | markets.businessinsider.comBrookline Capital Downgrades POINT Biopharma Global (PNT)December 22, 2023 | msn.comPOINT Biopharma Global Stock (NASDAQ:PNT), Guidance and ForecastDecember 22, 2023 | benzinga.comPOINT Biopharma Global (NASDAQ:PNT) Receives Hold Rating from Brookline Capital ManagementBrookline Capital Management reissued a "hold" rating and set a $12.50 price objective (down previously from $27.00) on shares of POINT Biopharma Global in a research note on Thursday.December 21, 2023 | marketbeat.comLilly extends tender offer for POINT Biopharma to Dec. 22December 18, 2023 | msn.comWhy POINT Biopharma Global Is At Least A Hold On Disappointing ReadoutDecember 18, 2023 | seekingalpha.comPOINT Biopharma Global Sees Unusually High Options Volume (NASDAQ:PNT)POINT Biopharma Global Inc. (NASDAQ:PNT - Get Free Report) saw unusually large options trading on Monday. Stock traders bought 20,626 call options on the company. This is an increase of approximately 162% compared to the average volume of 7,869 call options.December 18, 2023 | marketbeat.comLantheus Holdings And POINT Biopharma Announced Lu-PNT2002 Phase 3 SPLASH Study ResultsDecember 18, 2023 | markets.businessinsider.comPOINT Biopharma Global Inc. (NASDAQ:PNT) Short Interest Down 28.1% in NovemberPOINT Biopharma Global Inc. (NASDAQ:PNT - Get Free Report) was the recipient of a large decrease in short interest in November. As of November 30th, there was short interest totalling 2,640,000 shares, a decrease of 28.1% from the November 15th total of 3,670,000 shares. Based on an average trading volume of 2,740,000 shares, the short-interest ratio is currently 1.0 days. Approximately 3.0% of the shares of the company are short sold.December 14, 2023 | marketbeat.comStock Traders Buy Large Volume of Put Options on POINT Biopharma Global (NASDAQ:PNT)POINT Biopharma Global Inc. (NASDAQ:PNT - Get Free Report) was the target of unusually large options trading activity on Wednesday. Traders bought 11,904 put options on the company. This is an increase of approximately 73% compared to the average daily volume of 6,892 put options.December 13, 2023 | marketbeat.comPOINT Biopharma Global Inc. (PNT) Upgraded to Buy: Here's What You Should KnowDecember 8, 2023 | msn.comLilly Says Tender Offer Expiration Extended Related To POINT Biopharma AcquisitionDecember 4, 2023 | markets.businessinsider.comTrading was temporarily halted for "PNT" at 07:12 PM with a stated reason of "News pending."December 4, 2023 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: POINT Biopharma Global (PNT), Regeneron (REGN) and Incyte (INCY)November 30, 2023 | markets.businessinsider.comHold Rating on POINT Biopharma Global: An Assessment of Acquisition Offer, Pipeline Updates, and Financial StabilityNovember 17, 2023 | markets.businessinsider.comLilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023November 17, 2023 | finance.yahoo.comTrading was temporarily halted for "PNT" at 07:11 PM with a stated reason of "News pending."November 17, 2023 | marketbeat.comPOINT Biopharma Global Stock (NASDAQ:PNT) Earnings Dates and Earning CallsNovember 15, 2023 | benzinga.comLilly Receives NRC Consent In Connection With Proposed Acquisition Of POINT BiopharmaNovember 15, 2023 | markets.businessinsider.comPiper Sandler Keeps Their Hold Rating on POINT Biopharma Global (PNT)November 15, 2023 | markets.businessinsider.comPOINT Biopharma Global (PNT) News: Johnson Fistel Investigates Proposed Sale; Is $12.50 a Fair Price?November 14, 2023 | benzinga.comPOINT Biopharma Global: Why The Market Believes That A Second Bidder May EmergeNovember 14, 2023 | seekingalpha.comRecap: POINT Biopharma Global Q3 EarningsNovember 13, 2023 | benzinga.comPOINT Biopharma Reports Loss In Q3, Flat With Last Year, A Week After Lilly Agreed To Acquire ItNovember 13, 2023 | markets.businessinsider.comPOINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business HighlightsNovember 13, 2023 | finance.yahoo.comEli Lilly extends expiration of tender offer to acquire Point BiopharmaNovember 8, 2023 | msn.comLilly Extends Tender Offer For POINT Biopharma Global Until Nov. 16November 8, 2023 | markets.businessinsider.comLilly Announces Extension of Tender Offer to Acquire POINT BiopharmaNovember 8, 2023 | finance.yahoo.comPoint Biopharma quickly gains as big holder comes out against Eli Lilly dealNovember 6, 2023 | msn.comHold Rating on POINT Biopharma Global: Prospects, Uncertainties, and Potential of PNT2002October 26, 2023 | markets.businessinsider.comPiper Sandler Downgrades POINT Biopharma Global (PNT)October 24, 2023 | msn.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of POINT Biopharma Global, Inc. (PNT)October 19, 2023 | barrons.comPOINT Biopharma trades through deal price with Eli LillyOctober 18, 2023 | msn.comHold Rating on POINT Biopharma Amid Acquisition Proposal Uncertainties and Potential RisksOctober 18, 2023 | markets.businessinsider.comRaymond James Downgrades POINT Biopharma Global (PNT)October 7, 2023 | msn.comPOINT BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of POINT ...October 6, 2023 | businesswire.comLilly eyes targeted cancer therapies with $1.4 billion Point Biopharma dealOctober 5, 2023 | reuters.comLilly To Acquire POINT Biopharma For $1.4 Bln In Cash; POINT Up In Pre MarketOctober 3, 2023 | markets.businessinsider.comCrude Oil Moves Higher; POINT Biopharma Global Shares JumpOctober 3, 2023 | markets.businessinsider.comCruise lines, spinoff slumps, Eli Lilly-Point deal: Trending StocksOctober 3, 2023 | finance.yahoo.comEli Lilly POINTs Toward Radiopharmaceutical AmbitionsOctober 3, 2023 | seekingalpha.comEli Lilly and Company: Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand TherapiesOctober 3, 2023 | finanznachrichten.deEli Lilly to acquire Point Biopharma in $1.4B dealOctober 3, 2023 | seekingalpha.comShareholder Alert: Ademi LLP investigates whether POINT Biopharma Global, Inc. has obtained a Fair Price in its transaction with Eli LillyOctober 3, 2023 | benzinga.com Get POINT Biopharma Global News Delivered to You Automatically Sign up to receive the latest news and ratings for PNT and its competitors with MarketBeat's FREE daily newsletter. Email Address PNT Media Mentions By Week PNT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PNT News Sentiment▼0.000.73▲Average Medical News Sentiment PNT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PNT Articles This Week▼00▲PNT Articles Average Week Get POINT Biopharma Global News Delivered to You Automatically Sign up to receive the latest news and ratings for PNT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Axsome Therapeutics News Grifols News Cytokinetics News Ionis Pharmaceuticals News Alkermes News Elanco Animal Health News Verona Pharma News Rhythm Pharmaceuticals News Prestige Consumer Healthcare News PTC Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PNT) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhy Elon put $51 million into thisWhile fear dominates the headlines, a silent breakthrough could turn panic into profit. The future of AI fa...True Market Insiders | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding POINT Biopharma Global Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share POINT Biopharma Global With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PNT Stock Free PNT Stock Alerts